Developer docs
API playgroundTry for free, no card

Search company profiles

Symbio

Full company profile

uuid0008glk

Namestring
Symbio
Legal namestring
Symbio Clinical Research GmbH
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Symbio is a US-based therapeutic-specialized contract research organization (CRO) focused exclusively on dermatology, aesthetics, gastroenterology, and inflammatory diseases. Founded in 2002 and headquartered in Port Jefferson, New York, the company delivers Phase I-IV clinical trial services for pharmaceutical, biotech, and medical device sponsors across 50+ countries. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring by qualified M.D.s with 10+ years of experience, regulatory affairs, medical writing, data management, and biostatistics, offered under both full-service and functional service provider (FSP) engagement models. Symbio cites 650+ clinical trials spanning 85+ indications with 70+ FDA approvals as accumulated track record.

The business model is project-based professional services revenue from enterprise pharma and biotech sponsors, sourced through an enterprise field sales motion organized regionally across the US and EMEA & APAC, complemented by heavy presence at specialty conferences (AAD, EADV, OCT, EAACI, ACE, Dermatology Drug Development Summit). The group expanded materially in November 2023 when Symbio, LLC and its Dow Development Laboratories subsidiary merged with Proinnovera GmbH under ARCHIMED private equity sponsorship, adding European scale and a vertically integrated topical formulation development and cGMP manufacturing capability through the 23,000 sq ft Petaluma, California DDL facility. A September 2024 rebrand unified the group under the Symbio name, and the company subsequently opened a new Australia office and legal entity in 2025 to establish Asia-Pacific presence.

The customer base consists of enterprise pharma and biotech sponsors developing dermatology drugs (acne, psoriasis, atopic dermatitis, rosacea), aesthetics products (dermal fillers, neurotoxins, energy-based devices), gastroenterology therapies (IBD, celiac, eosinophilic GI disorders, IBS), and inflammatory disease treatments (urticaria, prurigo nodularis, atopic dermatitis). Pricing is quote-based and project-specific, tied to study scope, phase, geography, and therapeutic complexity, and is not publicly disclosed. Strategically, the value proposition combines domain depth and investigator/site relationships built over 20+ years with turnkey capability spanning formulation development through regulatory submission, supported by ancillary tax advantages such as the French Crédit d'Impôt Recherche (CIR) certification.

Short descriptiontext

Symbio is a therapeutic-specialized CRO delivering end-to-end Phase I-IV clinical trial services in dermatology, aesthetics, gastroenterology, and inflammation for enterprise pharmaceutical and biotech sponsors across 50+ countries, supplemented by in-house topical formulation manufacturing through its Dow Development Laboratories subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPort Jefferson Station, United States
HQ citystring
Port Jefferson Station
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, dermatology clinical trials, topical formulation development, medical device studies
Industry5 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CRO Services (Full-Service and FSP)
TypeProfessional Services
Description

End-to-end clinical trial solutions as a full-service CRO or functional service provider (FSP) for dermatology, aesthetics, gastroenterology, and inflammation drug and device development. Services include clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, biostatistics, and topical formulation development. Revenue is generated through service contracts with pharmaceutical and biotech sponsors.

symbioresearch.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Dow Development Laboratories (DDL)
Description

Subsidiary specializing in the design, development, and manufacture of topical drug products; FDA-registered and cGMP compliant

symbioresearch.com
+1 more record
Core offering1 text field

Symbio is a therapeutic-focused Contract Research Organization (CRO) that delivers end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors in dermatology, aesthetics, gastroenterology, and inflammation. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics, delivered via full-service or functional service provider (FSP) models. Through its subsidiary Dow Development Laboratories (DDL), Symbio also provides turnkey topical drug product formulation design, development, and cGMP clinical supply manufacturing from a 23,000 sq ft FDA-registered facility in Northern California.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 404 patients randomized in approximately 4.2 months with ~92% randomization rate and ~94% patient retention in a global Phase 3 psoriasis trial across 30 sites.
+2 more records
Product overview1 text field

Symbio is a therapeutic-focused Contract Research Organization (CRO) offering end-to-end clinical trial solutions through a unified platform. The portfolio consists of Symbio Clinical Research Services as the core CRO offering, complemented by Dow Development Laboratories (DDL) subsidiary for topical formulation development and manufacturing. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics. The company specializes in four therapeutic areas: dermatology, aesthetics, gastroenterology, and inflammation, supporting Phase I-IV drug and device trials globally.

Product and service6 records
1Symbio Clinical Research Services
CategoryContract Research Organization (CRO) Services
Description

Full-service and Functional Service Provider (FSP) Contract Research Organization offering end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors across dermatology, aesthetics, gastroenterology, and inflammation drug and device development globally.

2Dow Development Laboratories (DDL) — Topical Formulation Development & Manufacturing
CategoryTopical Pharmaceutical Manufacturing (CDMO)
Description

FDA-registered, cGMP-compliant subsidiary providing topical drug product formulation design, development, and manufacturing at a 23,000 sq ft facility in Petaluma, CA; supports IND, NDA, and ANDA programs for sponsors developing topical therapeutics.

3Dermatology Clinical Trials
CategoryDermatology CRO Services
Description

Specialized clinical trial management from formulation development through global trials to final approval for dermatology indications including acne, psoriasis, atopic dermatitis, rosacea, and rare skin diseases; full Phase I-IV delivery plus medical device studies for pharmaceutical and biotech sponsors.

4Aesthetics Clinical Trials
CategoryAesthetics CRO Services
Description

Specialized clinical trials and regulatory support for aesthetic products including dermal fillers, neurotoxins, botulinum toxins, submental fat treatments, medical devices, energy-based aesthetic devices, and injectables; expertise in MDR Annex XVI and FDA regulatory requirements.

5Gastroenterology Clinical Trials
CategoryGastroenterology CRO Services
Description

Specialized gastroenterology clinical trials addressing patient recruitment for difficult populations, specialized endpoints, biomarker integration, and regulatory submissions across global markets; indications include IBD, celiac disease, eosinophilic GI disorders, and IBS.

6Inflammatory Disease Clinical Trials
CategoryInflammation CRO Services
Description

Specialized clinical trials for inflammatory diseases across dermatology, gastroenterology, and immunology indications; including urticaria, psoriasis, atopic dermatitis, prurigo nodularis, and rare inflammatory skin conditions; supports evolving therapeutic targets such as JAK inhibitors and biologics.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dow Development Laboratories (DDL) is a subsidiary of Symbio, specializing in the design, development, and manufacture of topical drug products. DDL is FDA-registered and cGMP compliant, occupying a 23,000 sq ft custom-built facility in Petaluma, California. The subsidiary enables Symbio to provide an integrated turnkey solution covering topical formulation development, GLP studies, GMP clinical supply manufacturing, and clinical packaging and labeling.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-size, therapeutically-focused CRO with strong expertise in dermatology, neuroscience, and cardiometabolic therapeutic areas. Directly comparable in business model (full-service and FSP), therapeutic specialization depth, and mid-size positioning competing for similar pharma/biotech sponsors.

TypeDirect peer
Description

Full-service CRO with strong therapeutic specialization and a high-touch operating model similar to Symbio's. Comparable in delivering Phase I-IV trials with focused therapeutic expertise and a reputation for operational excellence in specialty indications.

TypeDirect peer
Description

Mid-size CRO with therapeutic specialization across multiple areas including dermatology and inflammation. Comparable in size, therapeutic focus, and full-service/FSP delivery model targeting similar pharma/biotech sponsors.

TypeDirect peer
Description

Dermatology-focused CRO specializing in skin and aesthetics trials, providing Phase I-IV services. Directly comparable niche therapeutic specialization in dermatology with similar target sponsor base.

TypeDirect peer
Description

Mid-size CRO with therapeutic focus areas including dermatology, oncology, and CNS. Comparable in size, therapeutic-area specialization strategy, and full-service delivery model for specialty pharma and biotech sponsors.

TypeBroad incumbent
Description

One of the largest global CROs offering full-service Phase I-IV capabilities across all major therapeutic areas. Broad incumbent competing for dermatology trials at the top end of the market, with significantly greater scale and global reach than Symbio.

TypeBroad incumbent
Description

World's largest CRO with comprehensive clinical research services across all therapeutic areas including dermatology. Broad incumbent whose dermatology practice competes with Symbio on large global trials with data, technology, and scale advantages.

TypeBroad incumbent
Description

Large global full-service CRO with therapeutic specialization including dermatology and inflammation. Competes with Symbio for full-service dermatology contracts with broader therapeutic coverage and larger scale.

TypeEmerging player
Description

Mid-size CRO offering full-service clinical research with therapeutic focus in oncology and other specialty areas. Comparable in size and operational model, with some therapeutic-area overlap relevant to Symbio's inflammation and gastroenterology practices.

TypeEmerging player
Description

Mid-size CRO formed from the merger of dMed and Clinipace, providing clinical development services across multiple therapeutic areas. Comparable in size and therapeutic focus strategy, with relevant overlap in specialty pharma trials.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Symbio

Contract Research Organization (CRO) Servicessymbioresearch.com

Symbio is a therapeutic-specialized CRO delivering end-to-end Phase I-IV clinical trial services in dermatology, aesthetics, gastroenterology, and inflammation for enterprise pharmaceutical and biotech sponsors across 50+ countries, supplemented by in-house topical formulation manufacturing through its Dow Development Laboratories subsidiary.

What Symbio does

Symbio is a US-based therapeutic-specialized contract research organization (CRO) focused exclusively on dermatology, aesthetics, gastroenterology, and inflammatory diseases. Founded in 2002 and headquartered in Port Jefferson, New York, the company delivers Phase I-IV clinical trial services for pharmaceutical, biotech, and medical device sponsors across 50+ countries. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring by qualified M.D.s with 10+ years of experience, regulatory affairs, medical writing, data management, and biostatistics, offered under both full-service and functional service provider (FSP) engagement models. Symbio cites 650+ clinical trials spanning 85+ indications with 70+ FDA approvals as accumulated track record.

The business model is project-based professional services revenue from enterprise pharma and biotech sponsors, sourced through an enterprise field sales motion organized regionally across the US and EMEA & APAC, complemented by heavy presence at specialty conferences (AAD, EADV, OCT, EAACI, ACE, Dermatology Drug Development Summit). The group expanded materially in November 2023 when Symbio, LLC and its Dow Development Laboratories subsidiary merged with Proinnovera GmbH under ARCHIMED private equity sponsorship, adding European scale and a vertically integrated topical formulation development and cGMP manufacturing capability through the 23,000 sq ft Petaluma, California DDL facility. A September 2024 rebrand unified the group under the Symbio name, and the company subsequently opened a new Australia office and legal entity in 2025 to establish Asia-Pacific presence.

The customer base consists of enterprise pharma and biotech sponsors developing dermatology drugs (acne, psoriasis, atopic dermatitis, rosacea), aesthetics products (dermal fillers, neurotoxins, energy-based devices), gastroenterology therapies (IBD, celiac, eosinophilic GI disorders, IBS), and inflammatory disease treatments (urticaria, prurigo nodularis, atopic dermatitis). Pricing is quote-based and project-specific, tied to study scope, phase, geography, and therapeutic complexity, and is not publicly disclosed. Strategically, the value proposition combines domain depth and investigator/site relationships built over 20+ years with turnkey capability spanning formulation development through regulatory submission, supported by ancillary tax advantages such as the French Crédit d'Impôt Recherche (CIR) certification.

Symbio firmographics

Firmographics
Name
Symbio
Legal name
Symbio Clinical Research GmbH
Website
https://symbioresearch.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Symbio is a therapeutic-specialized CRO delivering end-to-end Phase I-IV clinical trial services in dermatology, aesthetics, gastroenterology, and inflammation for enterprise pharmaceutical and biotech sponsors across 50+ countries, supplemented by in-house topical formulation manufacturing through its Dow Development Laboratories subsidiary.
Ownership category
akta.pro rank

Symbio industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs

Keywords

  • Clinical research services
  • Contract research organization
  • Dermatology clinical trials
  • Topical formulation development
  • Medical device studies

Where Symbio is headquartered

Location

Headquarters

HQ city
Port Jefferson Station
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Symbio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. CRO Services (Full-Service and FSP): End-to-end clinical trial solutions as a full-service CRO or functional service provider (FSP) for dermatology, aesthetics, gastroenterology, and inflammation drug and device development. Services include clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, biostatistics, and topical formulation development. Revenue is generated through service contracts with pharmaceutical and biotech sponsors.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Symbio product offering

Product offering

Core offering

Symbio is a therapeutic-focused Contract Research Organization (CRO) that delivers end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors in dermatology, aesthetics, gastroenterology, and inflammation. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics, delivered via full-service or functional service provider (FSP) models. Through its subsidiary Dow Development Laboratories (DDL), Symbio also provides turnkey topical drug product formulation design, development, and cGMP clinical supply manufacturing from a 23,000 sq ft FDA-registered facility in Northern California.

Product overview

Symbio is a therapeutic-focused Contract Research Organization (CRO) offering end-to-end clinical trial solutions through a unified platform. The portfolio consists of Symbio Clinical Research Services as the core CRO offering, complemented by Dow Development Laboratories (DDL) subsidiary for topical formulation development and manufacturing. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics. The company specializes in four therapeutic areas: dermatology, aesthetics, gastroenterology, and inflammation, supporting Phase I-IV drug and device trials globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Dow Development Laboratories (DDL): Subsidiary specializing in the design, development, and manufacture of topical drug products; FDA-registered and cGMP compliant
  • Proinnovera

Products and services

  • Symbio Clinical Research Services Full-service and Functional Service Provider (FSP) Contract Research Organization offering end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors across dermatology, aesthetics, gastroenterology, and inflammation drug and device development globally.
  • Dow Development Laboratories (DDL) — Topical Formulation Development & Manufacturing FDA-registered, cGMP-compliant subsidiary providing topical drug product formulation design, development, and manufacturing at a 23,000 sq ft facility in Petaluma, CA; supports IND, NDA, and ANDA programs for sponsors developing topical therapeutics.
  • Dermatology Clinical Trials Specialized clinical trial management from formulation development through global trials to final approval for dermatology indications including acne, psoriasis, atopic dermatitis, rosacea, and rare skin diseases; full Phase I-IV delivery plus medical device studies for pharmaceutical and biotech sponsors.
  • Aesthetics Clinical Trials Specialized clinical trials and regulatory support for aesthetic products including dermal fillers, neurotoxins, botulinum toxins, submental fat treatments, medical devices, energy-based aesthetic devices, and injectables; expertise in MDR Annex XVI and FDA regulatory requirements.
  • Gastroenterology Clinical Trials Specialized gastroenterology clinical trials addressing patient recruitment for difficult populations, specialized endpoints, biomarker integration, and regulatory submissions across global markets; indications include IBD, celiac disease, eosinophilic GI disorders, and IBS.
  • Inflammatory Disease Clinical Trials Specialized clinical trials for inflammatory diseases across dermatology, gastroenterology, and immunology indications; including urticaria, psoriasis, atopic dermatitis, prurigo nodularis, and rare inflammatory skin conditions; supports evolving therapeutic targets such as JAK inhibitors and biologics.

Quantifiable outcome

  • 404 patients randomized in approximately 4.2 months with ~92% randomization rate and ~94% patient retention in a global Phase 3 psoriasis trial across 30 sites.
  • +2 more outcomes

Companies that use Symbio

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Symbio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Symbio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Dow Development Laboratories (DDL)coreStrategic or Co-development PartnerDow Development Laboratories (DDL) is a subsidiary of Symbio, specializing in the design, development, and manufacture of topical drug products. DDL is FDA-registered and cGMP compliant, occupying a 23,000 sq ft custom-built facility in Petaluma, California. The subsidiary enables Symbio to provide an integrated turnkey solution covering topical formulation development, GLP studies, GMP clinical supply manufacturing, and clinical packaging and labeling.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Symbio competitors and assessment

Company assessment

Direct peers

  • Worldwide Clinical Trials: Mid-size, therapeutically-focused CRO with strong expertise in dermatology, neuroscience, and cardiometabolic therapeutic areas. Directly comparable in business model (full-service and FSP), therapeutic specialization depth, and mid-size positioning competing for similar pharma/biotech sponsors.
  • Medpace: Full-service CRO with strong therapeutic specialization and a high-touch operating model similar to Symbio's. Comparable in delivering Phase I-IV trials with focused therapeutic expertise and a reputation for operational excellence in specialty indications.
  • CTI Clinical Trial & Consulting Services: Mid-size CRO with therapeutic specialization across multiple areas including dermatology and inflammation. Comparable in size, therapeutic focus, and full-service/FSP delivery model targeting similar pharma/biotech sponsors.
  • Therapeutics Inc. Dermatology-focused CRO specializing in skin and aesthetics trials, providing Phase I-IV services. Directly comparable niche therapeutic specialization in dermatology with similar target sponsor base.
  • Biorasi: Mid-size CRO with therapeutic focus areas including dermatology, oncology, and CNS. Comparable in size, therapeutic-area specialization strategy, and full-service delivery model for specialty pharma and biotech sponsors.

Broad incumbents

  • ICON plc: One of the largest global CROs offering full-service Phase I-IV capabilities across all major therapeutic areas. Broad incumbent competing for dermatology trials at the top end of the market, with significantly greater scale and global reach than Symbio.
  • IQVIA: World's largest CRO with comprehensive clinical research services across all therapeutic areas including dermatology. Broad incumbent whose dermatology practice competes with Symbio on large global trials with data, technology, and scale advantages.
  • Parexel: Large global full-service CRO with therapeutic specialization including dermatology and inflammation. Competes with Symbio for full-service dermatology contracts with broader therapeutic coverage and larger scale.

Emerging players

  • Clinipace Worldwide: Mid-size CRO offering full-service clinical research with therapeutic focus in oncology and other specialty areas. Comparable in size and operational model, with some therapeutic-area overlap relevant to Symbio's inflammation and gastroenterology practices.
  • Caidya: Mid-size CRO formed from the merger of dMed and Clinipace, providing clinical development services across multiple therapeutic areas. Comparable in size and therapeutic focus strategy, with relevant overlap in specialty pharma trials.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Symbio social profiles

Digital presence

Symbio compliance and trust

Trust signal

Compliance3 records

Symbio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Symbio leadership team

Management profile

Number of profiles

Profiles23 records

Symbio subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Symbio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Symbio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symbio

What does Symbio do?

Symbio is a therapeutic-focused Contract Research Organization (CRO) that delivers end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors in dermatology, aesthetics, gastroenterology, and inflammation. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics, delivered via full-service or functional service provider (FSP) models. Through its subsidiary Dow Development Laboratories (DDL), Symbio also provides turnkey topical drug product formulation design, development, and cGMP clinical supply manufacturing from a 23,000 sq ft FDA-registered facility in Northern California.

Is Symbio a public or private company?

Symbio is a private company. It is classified as private equity controlled and is currently operating.

When was Symbio founded?

Symbio was founded in 2002. It employs 101 to 250 people.

Where is Symbio based?

Symbio is headquartered in Port Jefferson Station, United States, in the North America region.

How does Symbio make money?

One revenue line is on record: CRO Services (Full-Service and FSP).

Who are Symbio's main competitors?

Direct peers on record are Worldwide Clinical Trials, Medpace, CTI Clinical Trial & Consulting Services, Therapeutics Inc. and Biorasi. Broad incumbents are ICON plc, IQVIA and Parexel. Emerging players are Clinipace Worldwide and Caidya.

Does Symbio have an API?

No public API is recorded for Symbio.

What industry is Symbio in?

Symbio's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TfscroTop Dermatology CROs for Eczema Research - TFS HealthScienceTFS HealthScience highlights the leading dermatology Contract Research Organizations (CROs) driving eczema research and treatment development. The article profiles five key firms, including Parexel and Symbio, noting that the global dermatology CRO market was valued at US$4.737 billion in 2022 with a projected growth rate of 6.8% through 2030.PR NewswireSymbio's South-East Asia Hub unlocks multi-country access with one interconnectSymbio Holdings launched its South-East Asia Regional Hub in Singapore and Malaysia, providing voice coverage across the region via a single interconnect. The hub aims to reduce costs for clients managing multiple interconnections and supports digital transformation, with plans to add more geographic and international number types.PR NewswireSymbio to unlock Malaysia domestic communications market with network launchSymbio Holdings launched its domestic network in Malaysia on May 12, 2023, with live call traffic and several global customers trialling it. The network offers nationwide calling, IP and toll-free numbers, and call services, aiming to double its addressable market. Upcoming releases include a self-service portal and number portability.ARNSymbio officially launches Malaysia network – ARNSymbio officially launched its domestic network in Malaysia, with live call traffic and trial customers including Dialpad, OpenText, Telnyx, and DIDLogic. The network offers nationwide calling, IP numbers, and toll-free numbers, and the CEO said it nearly doubles the company's total addressable market. Upcoming releases include a self-service portal and number portability.ABN NewswireSymbio Holdings Limited (ASX:SYM) Trading Update - Confirms GuidanceSymbio Holdings confirmed FY23 EBITDA guidance of $26-28 million, citing stabilised market conditions and organic growth across its divisions. The company plans to expand into Singapore, Malaysia, and Taiwan, increasing its total addressable market by 170% to 100 million people by 2024. Malaysia customer trials are scheduled for 12 May 2023.PR NewswireSymbio extends its Asia expansion into TaiwanSymbio Holdings announced it will open service availability in Taiwan in 2023, following its 2021 Singapore entry. The move supports its plan to enter five new APAC countries by 2025, including Malaysia, South Korea, Japan, and Vietnam. The company aims to support 100 million numbers by 2030.ABN NewswireSymbio Holdings Limited (ASX:SYM) 2022 Full Year Results Date and WebinarSymbio Holdings will release its FY2022 financial results on 29 August 2022, followed by a CEO-led webinar. The company, a cloud communication software provider, powers billions of calls and messages annually.PR Newswire APACSymbio partners with Cisco to launch Webex Calling solution in SingaporeSymbio Holdings launched a unified communications solution for Cisco's Cloud Connect for Webex Calling in Singapore, available to Cisco resellers. The cloud-native solution removes on-premise infrastructure, reducing hardware and deployment costs. It builds on Symbio's 2021 entry and partnerships in Australia and New Zealand.ABN NewswireSymbio Holdings Limited (ASX:SYM) Investor DaySymbio Holdings will hold an investor day on June 22, 2022, at 10:30 am AEST to present its strategy and Asian expansion. CEO Rene Sugo and executives will provide updates, product demos, and invite industry guests to discuss CPaaS and UCaaS opportunities. The event will be streamed live.iTWireSymbio selects Mihaila to lead CPaaS divisionSymbio Holdings appointed Giorgio Mihaila as CEO of its CPaaS division, effective 1 July 2022. He joins from Webex by Cisco, where he was VP and GM for collaboration and customer experience. Mihaila will be based in North America and aims to drive growth in the APAC region.